Baker Bros. Decreases Exposure at Viropharma
Julian and Felix Baker's hedge fund, Baker Bros. Advisors, now holds around 4.4 million shares of Viropharma Inc (NASDAQ:VPHM), a newly amended filing with the SEC has revealed. Baker Bros.
Viropharma Inc (VPHM)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Granite Point Capital Warren Lammert | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | Water Island Capital John Orrico | 0 | $0 | 0% | |
| 4. | Springbok Capital Gavin Saitowitz And Cisco J. Del Valle | 0 | $0 | 0% | |
| 5. | Twin Capital Management David Simon | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.07 | 2,500 | $62,675.00 | 7,000 | 2012-12-03 | Filing | |
| $27.29 | 7,828 | $213,612.81 | 303,264 | 2011-12-14 | Filing | |
| $27.29 | 291,706 | $7,960,160.84 | 9,840,469 | 2011-12-14 | Filing | |
| $27.29 | 50,566 | $1,379,860.18 | 1,966,090 | 2011-12-14 | Filing | |
| $18.18 | 16,278 | $295,984.50 | 1,915,524 | 2011-10-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.53 | 17,500 | $394,301.25 | 20,167 | 2012-12-24 | Filing | |
| $22.53 | 17,500 | $394,301.25 | 37,667 | 2012-12-24 | Filing | |
| $23.87 | 60,000 | $1,431,954.00 | 104,500 | 2012-12-13 | Filing | |
| $24.07 | 14,999 | $360,983.93 | 37,667 | 2012-12-10 | Filing | |
| $24.07 | 50,000 | $1,203,360.00 | 37,667 | 2012-12-10 | Filing |
Institutional Investors' Holdings
News See All
Sanofi SA (ADR) (SNY), Regeneron Pharmaceuticals Inc (REGN): Getting Closer
French drugmaker Sanofi SA (ADR) (NYSE:SNY) counted that much money in its coffers as of the end of June, including cash, cash equivalents, and short-term investments.
Sanofi SA (ADR) (SNY), Shire PLC (ADR) (SHPG): Making Sense of the Drama About Viropharma Inc (VPHM)
In the world of small biotech companies, investors are always fishing for the next small fish to be gobbled up by a bigger one since the industry is well-known for its hefty acquisition premiums. Viropharma...
Regeneron Pharmaceuticals Inc (REGN), Viropharma Inc (VPHM): Sanofi SA (ADR) (SNY)'s Interest Sparks Biotech Stocks in a Huge Week for Investors
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Viropharma Inc (VPHM): Are Hedge Funds Right About This Stock?
If you were to ask many traders, hedge funds are seen as useless, old investment vehicles of an era lost to time.
Hedge Funds Aren't Crazy About Charles River Laboratories (CRL) Anymore
In today’s marketplace, there are dozens of gauges shareholders can use to watch stocks. A pair of the most innovative are hedge fund and insider trading movement.
Is Questcor Pharmaceuticals Inc (QCOR) Going to Burn These Hedge Funds?
In today’s marketplace, there are a multitude of methods shareholders can use to watch stocks. A pair of the most under-the-radar are hedge fund and insider trading activity.
Hedge Funds Are Selling Arena Pharmaceuticals, Inc. (ARNA)
Now, according to many market players, hedge funds are viewed as delayed, outdated financial tools of an era lost to time.
Alnylam Pharmaceuticals, Inc. (ALNY): Insiders Aren't Crazy About It But Hedge Funds Love It
If you were to ask many market players, hedge funds are seen as useless, outdated financial tools of a period lost to current times.
Arena Pharmaceuticals, Inc. (ARNA): What Do The Smartest Investors Think?
In the financial world, there are tons of indicators investors can use to watch their holdings. Some of the most under-the-radar are hedge fund and insider trading sentiment.